Quantitative cone contrast threshold testing in patients with differing pathophysiological mechanisms causing retinal diseases.
Quantitative cone contrast threshold testing in patients with differing pathophysiological mechanisms causing retinal diseases.
复制标题
DOI：
10.1186/s40942-023-00442-3
复制
发表时间：
2023-02-02
影响因子：
2.3
通讯作者：
中科院分区：
文献类型：
--
作者：
视锥对比阈值测试（CCT）提供了颜色和对比功能的定量测量，以揭示视觉质量的变化，而这些变化在临床试验中不是标准终点。我们利用CCT测量多发性硬化症（MS）、年龄相关性黄斑变性（AMD）、视网膜前膜（ERM）和视网膜静脉闭塞（RVO）患者的视觉功能。回顾性数据来自加文·赫伯特眼科研究所的237名患者。研究对象包括17例MS患者、45例AMD患者、41例ERM患者、11例RVO患者和123名健康对照。患者在正常护理期间接受了主要测量结果、CCT测试、斯隆视力测试和光谱域光学相干断层扫描。无论是否有视神经炎病史，MS患者均存在颜色和对比缺陷。中度或更严重疾病的AMD显示CCT评分降低。所有三个阶段的ERM均表现为视锥对比缺损。尽管视力恢复，rvo影响的眼睛比未受影响的眼睛表现出更差的CCT表现。CCT显示具有不同病理生理的多种视网膜疾病的颜色和对比度缺陷。进一步的前瞻性研究CCT在其他疾病状态和更大的样本量是必要的。在线版本包含补充材料，可在10.1186/s40942-023-00442-3获得。
Cone contrast threshold testing (CCT) provides quantitative measurements of color and contrast function to reveal changes in vision quality that are not standard endpoints in clinical trials. We utilize CCT to measure visual function in patients with multiple sclerosis (MS), age-related macular degeneration (AMD), epiretinal membrane (ERM), and retinal vein occlusion (RVO). Retrospective data was gathered from 237 patients of the Gavin Herbert Eye Institute. Subjects included 17 patients with MS, 45 patients with AMD, 41 patients with ERM, 11 patients with RVO, and 123 healthy controls. Patients underwent the primary measurement outcome, CCT testing, as well as Sloan visual acuity test and spectral domain optical coherence tomography during normal care. Color and contrast deficits were present in MS patients regardless of history of optic neuritis. AMD with intermediate or worse disease demonstrated reduced CCT scores. All 3 stages of ERM demonstrated cone contrast deficits. Despite restoration of visual acuity, RVO-affected eyes demonstrated poorer CCT performance than unaffected fellow eyes. CCT demonstrates color and contrast deficits for multiple retinal diseases with differing pathophysiology. Further prospective studies of CCT in other disease states and with larger samples sizes is warranted. The online version contains supplementary material available at 10.1186/s40942-023-00442-3.